UNSPSC 85811307: Introduction of other antineoplastic into pleural cavity, via natural or artificial opening

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of other antineoplastic into pleural cavity, via natural or artificial opening. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0L705

UNSPSC 85811307 (Introduction of other antineoplastic into pleural cavity, via natural or artificial opening) is a Commodity code that shows little relevant recent state and local procurement activity. The code nominally describes a clinical procedure—intracavitary chemotherapy administration—yet the recent opportunities tagged under this code involve telehealth platforms, occupational health services, cancer screening, cancer registry services, wellness programs, medical director appointments, and opioid treatment initiatives that bear no meaningful connection to the procedure itself. State and local procurement data systems occasionally misclassify opportunities at the commodity level, and this code appears to be an example of systematic miscoding rather than active market activity aligned with the code's stated scope.

Recent opportunities showing no relationship to the code's clinical focus span issuing bodies including health plans (Inland Empire Health Plan in California), county health departments and behavioral health systems (Ventura County, Santa Clara County, Fairfax County, Sedgwick County), municipalities (City of Phoenix, City of Ocala, City of Atlanta), school districts (Parkway School District), state agencies (Texas HHSC, Colorado Department of Human Services, Nevada Health Authority, Illinois Secretary of State), and special-purpose districts across California, Colorado, Kansas, Florida, Georgia, Oregon, and Texas. The volume and diversity of these misfiled procurements suggest the code itself is not a reliable classifier for state and local buying patterns, and pursuing opportunities under this code is not recommended without direct verification that the issuing body's actual scope aligns with intracavitary antineoplastic therapy.